Does the media prefer ADMA or ACAD?

In the previous week, ADMA Biologics had 27 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 38 mentions for ADMA Biologics and 11 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.93 beat ADMA Biologics' score of 0.04 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 3 Positive mention(s) 32 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SYRE or ADMA?

In the previous week, ADMA Biologics had 28 more articles in the media than Spyre Therapeutics. MarketBeat recorded 38 mentions for ADMA Biologics and 10 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.42 beat ADMA Biologics' score of 0.04 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 1 Very Positive mention(s) 3 Positive mention(s) 32 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, QGEN or ADMA?

Qiagen has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.88 $424.88M $1.91 20.61 ADMA Biologics $510.17M 3.97 $146.93M $0.68 12.86

Is QGEN or ADMA more profitable?

ADMA Biologics has a net margin of 32.43% compared to Qiagen's net margin of 19.16%. ADMA Biologics' return on equity of 39.98% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% ADMA Biologics 32.43% 39.98% 28.08%

Does the media favor QGEN or ADMA?

In the previous week, ADMA Biologics had 33 more articles in the media than Qiagen. MarketBeat recorded 38 mentions for ADMA Biologics and 5 mentions for Qiagen. ADMA Biologics' average media sentiment score of 0.04 beat Qiagen's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 1 Very Positive mention(s) 3 Positive mention(s) 32 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to KYMR or ADMA?

In the previous week, Kymera Therapeutics had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 43 mentions for Kymera Therapeutics and 38 mentions for ADMA Biologics. Kymera Therapeutics' average media sentiment score of 0.09 beat ADMA Biologics' score of 0.04 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 1 Very Positive mention(s) 3 Positive mention(s) 32 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

ADMA Biologics (ADMA) Competitors

$8.74 +0.03 (+0.29%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$8.72 -0.02 (-0.29%)

As of 06/26/2026 07:59 PM Eastern

Compare

ADMA vs. ACAD, ALLO, SYRE, QGEN, and KYMR

Should you buy ADMA Biologics stock or one of its competitors? MarketBeat compares ADMA Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ADMA Biologics include ACADIA Pharmaceuticals (ACAD), Allogene Therapeutics (ALLO), Spyre Therapeutics (SYRE), Qiagen (QGEN), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

ADMA Biologics (NASDAQ:ADMA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to ADMA Biologics' net margin of 32.43%. ADMA Biologics' return on equity of 39.98% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ADMA Biologics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

ADMA Biologics presently has a consensus target price of $19.67, indicating a potential upside of 124.89%. ACADIA Pharmaceuticals has a consensus target price of $31.63, indicating a potential upside of 24.90%. Given ADMA Biologics' higher probable upside, equities analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.97	$146.93M	$0.68	12.86
ACADIA Pharmaceuticals	$1.07B	4.05	$391M	$2.20	11.51

In the previous week, ADMA Biologics had 27 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 38 mentions for ADMA Biologics and 11 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.93 beat ADMA Biologics' score of 0.04 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	3 Positive mention(s)	32 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats ADMA Biologics on 11 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Allogene Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

ADMA Biologics has a net margin of 32.43% compared to Allogene Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Allogene Therapeutics	N/A	-56.45%	-40.36%

ADMA Biologics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.97	$146.93M	$0.68	12.86
Allogene Therapeutics	$20K	36,758.48	-$190.89M	-$0.77	N/A

ADMA Biologics currently has a consensus target price of $19.67, indicating a potential upside of 124.89%. Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 300.10%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, ADMA Biologics had 37 more articles in the media than Allogene Therapeutics. MarketBeat recorded 38 mentions for ADMA Biologics and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.87 beat ADMA Biologics' score of 0.04 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ADMA Biologics	Neutral
Allogene Therapeutics	Very Positive

Summary

ADMA Biologics beats Allogene Therapeutics on 9 of the 17 factors compared between the two stocks.

How does ADMA Biologics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

ADMA Biologics has a net margin of 32.43% compared to Spyre Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
ADMA Biologics	32.43%	39.98%	28.08%

Spyre Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

Spyre Therapeutics presently has a consensus target price of $95.83, indicating a potential upside of 9.04%. ADMA Biologics has a consensus target price of $19.67, indicating a potential upside of 124.89%. Given ADMA Biologics' higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ADMA Biologics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,575.69	-$155.20M	-$2.08	N/A
ADMA Biologics	$510.17M	3.97	$146.93M	$0.68	12.86

In the previous week, ADMA Biologics had 28 more articles in the media than Spyre Therapeutics. MarketBeat recorded 38 mentions for ADMA Biologics and 10 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.42 beat ADMA Biologics' score of 0.04 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	1 Very Positive mention(s)	3 Positive mention(s)	32 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

ADMA Biologics beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does ADMA Biologics compare to Qiagen?

Qiagen (NYSE:QGEN) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Qiagen has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Qiagen has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61
ADMA Biologics	$510.17M	3.97	$146.93M	$0.68	12.86

Qiagen currently has a consensus price target of $43.15, indicating a potential upside of 9.62%. ADMA Biologics has a consensus price target of $19.67, indicating a potential upside of 124.89%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ADMA Biologics had 33 more articles in the media than Qiagen. MarketBeat recorded 38 mentions for ADMA Biologics and 5 mentions for Qiagen. ADMA Biologics' average media sentiment score of 0.04 beat Qiagen's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	1 Very Positive mention(s)	3 Positive mention(s)	32 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ADMA Biologics has a net margin of 32.43% compared to Qiagen's net margin of 19.16%. ADMA Biologics' return on equity of 39.98% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
ADMA Biologics	32.43%	39.98%	28.08%

Summary

ADMA Biologics beats Qiagen on 9 of the 17 factors compared between the two stocks.

How does ADMA Biologics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Kymera Therapeutics currently has a consensus target price of $118.18, indicating a potential upside of 9.31%. ADMA Biologics has a consensus target price of $19.67, indicating a potential upside of 124.89%. Given ADMA Biologics' higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ADMA Biologics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	226.83	-$311.35M	-$3.57	N/A
ADMA Biologics	$510.17M	3.97	$146.93M	$0.68	12.86

Kymera Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

In the previous week, Kymera Therapeutics had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 43 mentions for Kymera Therapeutics and 38 mentions for ADMA Biologics. Kymera Therapeutics' average media sentiment score of 0.09 beat ADMA Biologics' score of 0.04 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	1 Very Positive mention(s)	3 Positive mention(s)	32 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

75.7% of ADMA Biologics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ADMA Biologics has a net margin of 32.43% compared to Kymera Therapeutics' net margin of -611.94%. ADMA Biologics' return on equity of 39.98% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
ADMA Biologics	32.43%	39.98%	28.08%

Summary

ADMA Biologics beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

Get ADMA Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADMA vs. The Competition

Export

Metric	ADMA Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.03B	$3.63B	$7.04B	$12.18B
Dividend Yield	N/A	2.22%	2.66%	6.24%
P/E Ratio	12.86	21.56	26.13	24.17
Price / Sales	3.97	334.22	600.49	118.86
Price / Cash	13.38	141.14	47.95	55.62
Price / Book	4.35	8.33	10.78	6.36
Net Income	$146.93M	$23.91M	$3.58B	$337.99M
7 Day Performance	5.23%	3.42%	2.22%	0.10%
1 Month Performance	10.28%	0.39%	-0.09%	-1.28%
1 Year Performance	-51.84%	65.22%	34.39%	27.68%

ADMA Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADMA ADMA Biologics	4.3907 of 5 stars	$8.75 +0.3%	$19.67 +124.9%	-51.8%	$2.03B	$510.17M	12.86	530	Trending News
ACAD ACADIA Pharmaceuticals	4.2349 of 5 stars	$22.09 +2.2%	$31.63 +43.2%	+14.5%	$3.70B	$1.07B	10.04	510	News Coverage Gap Up
ALLO Allogene Therapeutics	3.2427 of 5 stars	$2.10 +5.0%	$8.52 +305.8%	+80.5%	$690.31M	$20K	N/A	310	Negative News
SYRE Spyre Therapeutics	1.7923 of 5 stars	$100.32 +13.6%	$94.17 -6.1%	+477.5%	$7.67B	$890K	N/A	73	News Coverage Analyst Forecast Insider Trade Gap Up High Trading Volume
QGEN Qiagen	3.2367 of 5 stars	$36.42 -1.4%	$44.98 +23.5%	-21.7%	$7.61B	$2.09B	19.02	5,654	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADMA) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, SYRE, QGEN, and KYMR

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Summary

How does ADMA Biologics compare to Spyre Therapeutics?

Summary

How does ADMA Biologics compare to Qiagen?

Summary

How does ADMA Biologics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, SYRE, QGEN, and KYMR

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Is ADMA or ACAD more profitable?

Do insiders and institutionals believe in ADMA or ACAD?

Which has more risk & volatility, ADMA or ACAD?

Do analysts recommend ADMA or ACAD?

Which has preferable valuation and earnings, ADMA or ACAD?

Does the media prefer ADMA or ACAD?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Is ADMA or ALLO more profitable?

Which has more volatility & risk, ADMA or ALLO?

Which has preferable earnings & valuation, ADMA or ALLO?

Do analysts rate ADMA or ALLO?

Do institutionals and insiders have more ownership in ADMA or ALLO?

Does the media prefer ADMA or ALLO?

Summary

How does ADMA Biologics compare to Spyre Therapeutics?

Is SYRE or ADMA more profitable?

Which has more volatility & risk, SYRE or ADMA?

Do analysts prefer SYRE or ADMA?

Do institutionals & insiders believe in SYRE or ADMA?

Which has better earnings and valuation, SYRE or ADMA?

Does the media favor SYRE or ADMA?

Summary

How does ADMA Biologics compare to Qiagen?

Which has more risk and volatility, QGEN or ADMA?

Do institutionals and insiders believe in QGEN or ADMA?

Which has higher valuation and earnings, QGEN or ADMA?

Do analysts prefer QGEN or ADMA?

Does the media favor QGEN or ADMA?

Is QGEN or ADMA more profitable?

Summary

How does ADMA Biologics compare to Kymera Therapeutics?

Do analysts recommend KYMR or ADMA?

Which has stronger valuation and earnings, KYMR or ADMA?

Which has more volatility & risk, KYMR or ADMA?

Does the media refer more to KYMR or ADMA?

Do insiders and institutionals believe in KYMR or ADMA?

Is KYMR or ADMA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools